Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit

被引：168

作者：

Busby, Robert W. ^{[1
]}

Bryant, Alexander P. ^{[1
]}

Bartolini, Wilmin P. ^{[1
]}

Cordero, Etchell A. ^{[1
]}

Hannig, Gerhard ^{[1
]}

Kessler, Marco M. ^{[1
]}

Mahajan-Miklos, Shalina ^{[1
]}

Pierce, Christine M. ^{[1
]}

Solinga, Robert M. ^{[1
]}

Sun, Li Jing ^{[1
]}

Tobin, Jenny V. ^{[1
]}

Kurtz, Caroline B. ^{[1
]}

Currie, Mark G. ^{[1
]}

机构：

[1] Ironwood Pharmaceut Inc, Cambridge, MA 02142 USA

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 2010年 / 649卷 / 1-3期

关键词：

Cyclic guanosine monophosphate; Chronic constipation; Guanylate cyclase C; Irritable bowel syndrome with constipation; Linaclotide; HEAT-STABLE ENTEROTOXIN; ESCHERICHIA-COLI; HCO3-SECRETION; PROTEIN-KINASE; GC-C; UROGUANYLIN; RECEPTOR; MICE; PEPTIDES; TOXIN;

D O I：

10.1016/j.ejphar.2010.09.019

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Linaclotide is a first-in class orally administered 14 amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation We have characterized the solution structure of linaclotide the in vitro binding and agonist activity to guanylate cyclase C receptors the stability of linaclotide under conditions mimicking the gastric environment oral bioavailability and the pharmacodynamic effects in rat models of gastrointestinal transit and intestinal secretion Nuclear magnetic resonance spectroscopy analysis determined that the molecular structure of linaclotide is stabilized by three intramolecular disulfide bridges Linaclotide exhibited high affinity and pH-independent binding (K-1 1 23-1 64 nM) to guanylate cyclase C receptors on human colon carcinoma T84 cells and concomitantly linaclotide binding resulted in a significant concentration-dependent accumulation of intracellular cyclic guanosine-3' 5'-monophosphate (cGMP) (EC50 99 nM) Linaclotide was stable after 3 h incubation in simulated gastric fluid (pH 1) and similarly was completely resistant to hydrolysis by pepsin Pharmacokinetic analysis of linaclotide showed very low oral bioavailability (0 1%) Orally administered linaclotide elicited a significant dose-dependent increase in gastrointestinal transit rates in rats at doses of >= 5 mu g/kg Exposure of surgically ligated small intestinal loops to linaclotide induced a significant increase in fluid secretion accompanied by a significant increase in intraluminal cGMP levels These results suggest that the guanylate cyclase C agonist linaclotide elicits potent pharmacological responses locally in the gastrointestinal tract and that orally administered guanylate cyclase C agonists may be capable of improving bowel habits in patients suffering from irritable bowel syndrome with constipation and chronic constipation (C) 2010 Elsevier B V All rights reserved

引用

页码：328 / 335

页数：8

共 43 条

[1] Gastrointestinal transit in mice treated with various extracts of date (Phoenix dactylifera L.) [J].